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Abstract
Background: A multiplicity of study designs such as gene candidate analysis, genome wide search
(GWS) and, recently, whole genome association studies have been employed for the identification
of the genetic components of essential hypertension (EH). Several genome-wide linkage studies of
EH and blood pressure-related phenotypes demonstrate that there is no single locus with a major
effect while several genomic regions likely to contain EH-susceptibility loci were validated by
multiple studies.
Methods: We carried out the clinical assessment of the entire adult population in a Sardinian
village (Talana) and we analyzed 16 selected families with 62 hypertensive subjects out of 267
individuals. We carried out a double GWS using a set of 902 uniformly spaced microsatellites and
a high-density SNPs map on the same group of families.
Results: Three loci were identified by both microsatellites and SNP scans and the obtained linkage
results showed a remarkable degree of similarity. These loci were identified on chromosome 2q24,
11q23.1–25 and 13q14.11–21.33. Further support to these findings is their broad description
present in literature associated to EH or related phenotypes. Bioinformatic investigation of these
loci shows several potential EH candidate genes, several of whom already associated to blood
pressure regulation pathways.
Conclusion: Our search for major susceptibility EH genetic factors evidences that EH in the
genetic isolate of Talana is due to the contribution of several genes contained in loci identified and
replicated by earlier findings in different human populations.
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Background
Essential hypertension (EH [MIM 145500]), defined as
chronically elevated blood pressure (BP) occurring in the
absence of other predisposing conditions, has a world-
wide prevalence of nearly 27% [1,2]. It is a major risk fac-
tor for stroke, heart disease and end-stage renal disease
[3]. Twin studies support the existence of genetic factors
and studies on the genetic basis of susceptibility to hyper-
tension have estimated that the heritability of blood pres-
sure (BP) levels is around 30%–35% [4]. EH is considered
a multifactorial disorder caused by multiple genetic vari-
ants, gene-gene interactions and environmental factors
[5].
Rare syndromic forms of hypertension show Mendelian
inheritance and some variants related to several of these
disorders were identified through positional cloning and
candidate-gene analyses [6]. Mutations underlying mono-
genic forms of hypertension are rare in the general popu-
lation. In most cases the risk to developing EH might be
related to multiple variants, each with small and interme-
diate effect and/or with an additive effect on pathways
related to EH [7,8].
The study of the genetic components of hypertension is
carried out by different approaches such as gene candidate
analysis, genome wide search (GWS) and, recently, by
whole genome association studies [9,10]. Several
genome-wide linkage studies of EH and BP-related phe-
notypes using populations of different origin demonstrate
that there is no single genomic region with a large effect
on BP or EH [11,12]. However, several genomic regions,
such as 1q, 2p, 3p, 6q, 7q, 12q, 15q, 17q, 18q, and 19p,
were validated by multiple studies and are likely to con-
tain EH-susceptibility loci [5,13]. These loci may contain
hundreds of genes and linkage studies using microsatellite
markers are not able to restrict these regions. Until
recently, the majority of hypertension GWS were per-
formed using low-density maps of STR markers with a
spacing of about 5–10 cM across the genome.
The improvement in high-throughput technologies for
single nucleotide polymorphisms (SNPs) genotyping has
opened up a rapid and economical way of whole genome
analysis. International databases containing millions
SNPs provide a highly dense map across the human
genome, and it is possible to achieve adequate power for
investigating genome variants associated to complex dis-
eases such as hypertension. Previous studies demon-
strated that a highly dense map of SNP markers can
increase the power to detect linkage and consequently
identify a disease locus more precisely [14] than would be
with low-density microsatellites maps.
To reduce genetic complexity, our group chose to study
Sardinian isolated populations where it is expected to find
a simplification of complex disease models [15,16]. As a
matter of fact, the probability of finding susceptibility
genes is higher because people share a common environ-
ment and an age-stratified uniform lifestyle minimizing
non-genetic variability and maximizing genetic effect.
In this study, we report a genome-wide linkage analysis of
families affected by essential hypertension in a genetic iso-
late called Talana located in the Ogliastra region in Cen-
tral-Eastern Sardinia. Mitochondrial analysis traces this
village original population back to the Neolithic era and
reveals one of the most genetically homogenous popula-
tions so far described [17]. We chose Talana for its pecu-
liar genetic features such as increased background linkage
disequilibrium [18] due to its demographic history that
has led to genetic drift and founder effects. We evaluate
LD parameters and effective population structure using a
dense whole genome SNPs map that evidence high values
of LD parameters and the presence of LD variability across
the genome [19]. There are potential advantages in the
choice of these kind of populations because of reduced
environmental complexity and a probably reduced
number of disease alleles. Some of the loci are expected to
have stronger genetic effects on the disease/trait under
analysis.
Here, we discuss the findings of whole genome analysis in
several families with patients affected by essential hyper-
tension living in Talana. Our genome-wide linkage analy-
sis were obtained utilizing an intermediately-dense STRs
set and a highly-dense SNPs map.
Methods
Population features
The Central-Eastern area of Sardinia called Ogliastra is
characterized by the presence of several distinct villages
with different history, immigration events and population
size [20]. Centenarian cultural isolation and conservatism
characterized the history of these communities. The rele-
vant features of this geographic area are similar environ-
mental conditions, high endogamy, low immigration and
remote origin. This region also appears genetically differ-
entiated from neighboring areas [19]. Our study has
focused on one of the most isolated of these villages called
Talana. During the past, this community (1127 residents),
lying in a mountainous zone, maintained few contacts
and exchanged few marriages with other villages in the
same geographical area. Genetic analyses of Y chromo-
some and mitochondrial DNA [17] show that more than
80% of the present-day population descend from about
twenty founders. This population has a higher level of
endogamy than what is found in the whole Ogliastra:
92% in Talana compared to the regional 80%. Extensive
historical and archival data allow an accurate reconstruc-
tion of the genealogy of each extant individual. These data
are collected in a structured and comprehensive genealogyBMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
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database that was used to cluster individuals in pedigrees
that connect up to 16 generations [21]. We used patient
list as input and utilized an application designed to find
in the database all the ancestors related to any member on
the input list.
Clinical assessment
People living in the village were invited to take part in the
study by invitations sent by mail to every family and
through public announcements. All the people participat-
ing in the study were volunteers. The personal data were
encrypted and kept separated from genetic and data. The
scientific content of the project was extensively explained
to all individuals participating in the study that signed
informed consent forms in accordance with the Helsinki
Declaration http://www.catholicdoctors.org.uk/
Helsinki_declaration.htm. The study was submitted and
approved to the Italian Ministry of University and
Research (MIUR) following the current Italian legislation.
Respondents underwent blood tests, anthropometric and
blood pressure measurements. Each volunteer was inter-
viewed by a health worker who collected socio demo-
graphic information, clinical and family history,
medication history and information about important risk
factors for EH: living habits, such as smoking, alcohol
consumption and physical activity.
BP was measured in both arms at initial assessment, at the
end of the 40 minutes interview and the arm with the
highest pressure was used consequently. After 2 or more
measurements, done according to the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure [22], if the person had
a systolic blood pressure (SBP) ≥ 140 mmHg or a diastolic
blood pressure (DBP) ≥ 90 mmHg, he/she was then
invited to undergo new measurement sessions in the next
few weeks. BP measurements were obtained from sitting
subjects and with at least two minutes interval between
each cuff inflation. Standard mercury sphygmomanome-
ters (Miniatur 300 B, Speidel & Keller) were used, and one
of 4 cuff sizes (pediatric, regular adult, large, or tight) was
chosen on the basis of the participant's arm circumfer-
ence. The auscultation method was used: Korotkoff phase
I and phase V sounds were used in order to determine SBP
and DBP levels.
Biochemical analyses (24 serologic and 22 hemogram
parameters) were done in our central laboratory in Per-
dasdefogu. Hematology parameters were evaluated using
the Coulter AcT 5 autoloader hematology analyzer from
Beckman Coulter (Fullerton, CA, USA). We directly meas-
ured CBC parameters (white blood cell count, red blood
cell count, hemoglobin, mean corpuscular volume and
platelets) and calculated coefficients following the manu-
facturer's specifications. Basic chemistries, electrolytes,
enzymes, full lipid profile and derived tests were per-
formed by using the VITROS dry-slide technology an
automated Vitros 250 Chemistry System (Orthoclinical
Diagnostics, Johnson & Johnson Gateway SM, US). We
analyzed the following serum parameters: fasting glucose,
creatinine, sodium, potassium, calcium, phosphorus,
chloride, magnesium, uricaemia, GOT/AST, GPT/ALT,
bilirubin, protein, albumin, cholinesterase, alkaline phos-
phates, cholesterol and triglycerides. LDL-C levels was
determined by the Friedewald formula: LDL-C = TC -
(HDL-C + TG/5).
For anthropometric measurements subjects were exam-
ined wearing only their underwear. Weight was deter-
mined on a portable electronic scale to the nearest 0.1 kg
and height was measured to the nearest 0.5 cm with a sta-
diometer. Subjects were without shoes, standing upright
with the head in the Frank-fort plane for height measure-
ments. The body mass index (BMI) in kg/m2 was calcu-
lated from weight divided by height squared.
Physicians entered all collected data on PCs using an elec-
tronic medical record based on the structured interview
drawn up by the study group. Such an electronic medical
record is made of several modules allowing consultation
of a pharmacological archive, according to the ATC classi-
fication, in order to correctly enter medicines taken by
patients and consultation of the ICD-IX for the correct
pathological classification. The common purpose of every
module is to obtain standardized information.
Hypertension or high BP was defined as mean SBP ≥ 140
mmHg, mean DBP ≥ 90 mmHg or current treatment for
hypertension, verifying the patient information on the
slips that the participants were invited to bring with them
to the interview. Awareness of hypertension reflects any
prior diagnosis of hypertension or high BP by a health
professional among the participants defined as having
high BP. Control of hypertension was defined as pharma-
cological treatment of hypertension associated with SBP <
140 mm Hg and DBP < 90 mm Hg.
Our study focused on essential hypertension and, for this
reason, we excluded all diabetic individuals, patients with
renal diseases and people with certain or possible second-
ary hypertension on the bases of the anamnesis and the
information provided by the local doctor that follow the
large part of the patients during the recent years. In partic-
ular, for the latter case we excluded obese people, patients
with insufficient or negative response to therapeutic drugs
or characterized by a rapid and marked increase in blood
pressure.
For the linkage study, we selected 99 severe hypertensive
subjects based on these criteria: i) age at onset ≤ 65 yrs; ii)
BMI ≤ 35; iii) PAD ≥ 95 mmHg or antihypertensive ther-BMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
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apy; iv) exclusion of diabetes; v) exclusion of secondary
hypertension; vi) exclusion of individuals with high con-
sumption of smoke and alcohol.
The choice of a rather elevated BMI cut off point was deter-
mined by the average BMI in Talana: 27.8 kg/m2 in males
and 26.3 kg/m2 in females. The village inhabitants are
short people with a rather stocky built (mean height is
1.64 m in males and 1.50 m in females).
Genetic Analysis: Microsatellites and SNPs
Genomic DNA was extracted from 7 ml of EDTA-treated
blood with standard methods. Genotyping of all the sam-
ples collected in Talana was done in collaboration the
NHLBI Mammalian genotyping Service of the Marshfield
laboratory under the direction of Dr. James L. Weber. Six
hundred and fifty-four markers distributed over the
genome were genotyped. To obtain a higher average
marker density, we utilized approximately an additional
400 markers selected from the ABI PRISM® Linkage Map-
ping Set version 2.5 HD5 (Applied Biosystems, Foster city,
CA). Polymerase chain reaction was carried out according
to standard protocols. Microsatellite products were
loaded on ABI PRISM 3730 DNA Analyzer (Applied Bio-
systems) and data were processed by GENEMAPPER v3.0
software. A total of 902 highly informative (mean hetero-
zigosity = 0.7) microsatellites distributed over the genome
(average spacing = 4.3 cM), except X and Y chromosomes,
were used for the statistical analysis.
SNPs genotyping was performed on the Affymetrix Gene-
Chip platform. We used the GeneChip® Human Mapping
500 K Array Set that comprises two arrays (the Nsp and Sty
arrays) capable of genotyping ~262,000 and ~238,000
SNPs, respectively. We followed the recommended proto-
col described in the Affymetrix manual. All DNA samples
were normalized to 50 ng/μl. Then, 5 μl (250 ng) of
dsDNA was digested with the appropriate restriction
enzyme and ligated to adapters using T4 DNA ligase. Sam-
ples were then PCR amplified using TITANIUM Taq
polymerase on a GeneAmp® PCR System 9700 gold plate
thermal cycler. PCR products were purified using the
Clontech purification kit followed by fragmentation.
Samples were then injected into cartridges, hybridized,
washed and stained. Mapping array images were obtained
using the GeneChip Scanner 3000 7 G plus. Genotypes
were called using the BRLMM (Bayesian Robust Linear
Model with Mahalanobis distance classifier) software.
Individual arrays not passing the 93% call rate, threshold
at P = 0.33, were considered a quality control failure and
subsequently re-genotyped.
The data (microsatellites and SNPs) were checked for typ-
ing inconsistencies with the pedigree structure using Ped-
Check [23], employing semi-automatic procedures to
investigate and to remove errors. Instances that could not
be resolved were treated as missing data.
After the above-mentioned data cleaning, additional gen-
otypes that were determined as erroneous by Merlin
default error-detection option, were removed.
Recently, we performed a population genetic study on
Ogliastra villages, including Talana, in order to compared
the extent of LD using a set comprising both commons
and informative SNPs in all communities and in a stand-
ard outbred population (30 HapMap CEU trios) [19]. The
mean heterozygosity of the markers was 0.345 and the
average of minor allele frequency (MAF) was 0.251. The
monomorphic SNPs (M-SNPs), were ~26% of the entire
SNPs list. The comparison with the HapMap samples
showed that 88.5% of the shared M-SNPs were monomor-
phic also in the CEU population and 10.89% showed a
MAF > 0 and <0.05. The metric LD map evidence that the
pattern of "plateaus", regions of high LD, and "steps",
regions of increased recombination tends to be shared
among Ogliastra vs CEU population. This pattern presum-
ably reflects the common distribution of recombination
hot spots across various populations. With the intention
of using SNPs genotypes for linkage analysis, we create a
informative set of SNPs useful for linkage studies using
only the informative list of the SNPs in both populations.
We selected a subset of 16300 highly informative biallelic
markers: we used as a cut off a Minimum Allele Frequency
(MAF) >0.02 and average spacing of 150 kb in reason of
the best compromise among informativity, spacing and
number of SNPs. All markers physical coordinates refer to
the NCBI September 2006 released annotation update for
the human genome (NCBI Build 36.2). Alleles are
expressed in the forward (+) strand of reference.
Families' selection
We reconstructed a single deep-rooted 16-generation ped-
igree that includes all the population of the Talana village
encompassing 5219 individuals with multiple inbreeding
loops. Mean inbreeding calculated from the genealogy
using a subset of 876 living individuals is 0.018 [SD ±
0.022]. All 99 selected affected individuals were clustered
in a smaller pedigree including 2,246 people in order to
reduce the number of subjects that was not directly con-
nected to the samples used in the present study (see figure
1). The mean kinship of 99 affected individuals was
0.0229. The complexity of these large genealogies, typical
of isolated populations, forbids using them directly for
linkage analysis and forces to break-up the pedigree in
sub-branches.
The clustering of affected individuals in various separate
families was performed using a semiautomatic approachBMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
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performed by a particular tool called FamPrep imple-
mented in the PedNavigator software [21]. This software,
starting from a list of subjects, allows to select the number
of generations and subsequently reconstructs various
genealogies. Selecting a mean number of 4 generations we
obtained 16 families that include 267 individuals (84
founders, 183 non-founders) comprehending 62 hyper-
tensive subjects (mean 3.87 for family, range 2–6). The
mean family size was 16.68 samples (range 8–25). Of the
267 individuals 141 were genotyped with STRs and 139
with SNPs with mean frequency of genotyped individuals
equal to 52.80% and 52.05% respectively. All affected
individuals were genotyped with both markers sets.
Statistical Analysis
As the inheritance pattern of EH is unknown, we used
non-parametric linkage analysis to assess evidence for
linkage. This type of test does not require specification of
inheritance pattern, disease allele frequency and pene-
trance rate. Moreover it tolerates phenotype definition
errors.
We used MERLIN (Multipoint Engine for Rapid Likeli-
hood Inference) software [24] to perform multipoint NPL
analysis using both the selected 16300 SNPs and 902 STRs
in the 16 families' data sets. MERLIN implements the
Whittemore and Halpern [25] algorithm to test for allele
sharing among affected individuals and also calculates a
nonparametric LOD score by use of the Kong and Cox
[26] linear model.
Linkage analysis assumes linkage equilibrium between
markers, but when dense maps are used, this assumption
is not respected and it can lead to inaccurate results, espe-
cially when parental genotypes are missing. We corrected
marker-marker linkage disequilibrium using the methods
implemented by MERLIN. This algorithm clusters tightly
linked markers and uses haplotypes frequencies to model
LD within each cluster. Carrying out STRs analysis, we
used the distance k as standard that inserts a cluster break-
point between markers that are less than k cM apart. We
used k = 2 cM. To evaluate LD values using SNPs, we cre-
ated clusters using r2>0.4 as parameter.
The Talana-specific STRs genetic maps were constructed
for all autosomal chromosomes using CRI-MAP [27] that
was run on an extended pedigree where the number of
informative meioses were maximized (up to 900 inform-
ative meioses). Allele frequencies were estimated from the
whole sample of genotyped subjects and average markers
heterozygosity was 0.71 (SD = 0.09). A confirmatory anal-
ysis was executed using Marshfield and Decode genetic
map distances in the mapping analysis.
Using STRs set, we evaluate genome-wide type I error rates
and estimate the threshold for statistical significance by
use of simulations [28]. We used the pedigree of 2,246
individuals including the 99 affected individuals and all
of the 267 persons belonging to 16 families for marker
simulations using the program Genedrop from the MOR-
GAN package http://www.stat.washington.edu/thomp
son/Genepi/MORGAN/Morgan.shtml. Number of mark-
ers, inter-marker distances and marker allele frequencies
were simulated according to the typed marker set. We per-
formed linkage analysis using Merlin in the 16 sub-pedi-
grees setting to "missing" the genotypes of individuals not
sampled. For each genome screen the highest LOD score
was stored. Cumulative density function of the obtained
maximum LOD scores approximates the distribution of
the type I error rates. We performed 1000 simulations for
STRs map and the results showed that LOD score of 2.42
corresponds to a genome-wide type I error of 5% and that
a LOD score of 1.77 corresponds a genome-wide type I
error of 50% (Figure 2). In SNPs analyses, we decided to
use the standard thresholds of significance (LOD score 3.3
for significant and LOD score of 1.9 for suggestive) [29]
because of high computational complexity and time con-
suming. Finally, we calculated the information content
(IC) that represents the major advantage of using high
density SNPs versus microsatellites. IC was calculated
using MERLIN to compare both sets of markers in order to
investigate factors contributing to different results
between the two scans.
The entire pedigree with 2,246 members, including 99 hyper- tensive patients, from the Talana population Figure 1
The entire pedigree with 2,246 members, including 
99 hypertensive patients, from the Talana popula-
tion. Men are represented with squares and women with 
circles. Affected individuals are represented in black. To sim-
plify, unaffected relatives of the patients included in the analy-
ses are not shown. This pedigree was drawn using Pedfiddler 
v. 0.5.B
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Table 1: Clinical characteristics of the studied population. 
DBP§
(mm Hg)
SBP§§
(mm Hg)
Age#
(Years)
Height
(cm)
Weight
(Kg)
BMI##
(Kg/m2)
Tot Chol *
(mg/dL)
HDL
(mg/dL)
LDL
(mg/dL)
Triglyce
rides
(mg/dL)
Treatment 
**
Males
(25)
92.81 ± 8.12 146.60 ± 13.50 56.92 ± 17.50 163.25 ± 5.26 78.20 ± 8.07 29.38 ± 3.06 196.50 ± 38.53 55.10 ± 9.84 116.52 ± 31.48 124.40 ± 37.58 69.23%
Females
(37)
88.91 ± 10.17 151.38 ± 15.22 58.38 ± 13.05 150.13 ± 5.16 63.83 ± 9.80 28.34 ± 4.17 206.42 ± 29.74 60.5 ± 13.55 122.71 ± 29.29 116.02 ± 49.06 59.52%
AFFECTED
(62)
90.38 ± 9.58 149.59 ± 14.68 57.86 ± 14.73 155.05 ± 8.22 69.22 ± 11.51 28.73 ± 3.80 203.00 ± 33.045 58.63 ± 12.57 120.57 ± 29.93 118.91 ± 45.27 63.23%
Males
(33)
80.56 ± 9.14 137.97 ± 15.38 63.94 ± 17.28 160.76 ± 6.20 69.73 ± 11.47 26.92 ± 3.84 190.05 ± 45.89 46.94 ± 11.55 122.49 ± 39.31 103.11 ± 41.48 -
Females
(46)
80.45 ± 6.99 131.95 ± 15.64 56.35 ± 14.70 149.15 ± 5.48 57.70 ± 11.17 25.74 ± 4.95 203.79 ± 33.62 64.55 ± 14.31 120.13 ± 31.72 95.51 ± 38.59 -
UNAFFECTED
(79)
80.51 ± 8.05 134.91 ± 15.68 60.03 ± 16.30 154.49 ± 8.21 63.24 ± 12.34 26.33 ± 4.99 199.90 ± 37.61 59.56 ± 15.68 120.80 ± 33.71 97.66 ± 39.23 -
TALANA
(654)***
79.87 ± 13.07 131.28 ± 21.01 51.87 ± 18.52 155.78 ± 9.56 65.60 ± 14.46 26.95 ± 5.03 194.31 ± 34.45 58.39 ± 12.67 114.53 ± 29.81 106.92 ± 58.51 -
All columns contain Mean values and Standard Deviations for each variable.
§DBP, Diastolic Blood Pressure; §S SBP, Systolic Blood Pressure; # Age, Age at examination; ## BMI, Body Mass Index; * Tot Chol, Total Cholesterol, ** Treatment, % taking antihypertensive 
medications for at least one year; *** Analyzed subjects >18 years.BMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
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Results
Descriptive clinical characteristics
In Talana, we were able to collect 654 voluntary partici-
pants older than 18 years with a mean age of 52 ± 18 (see
table 1). The sample included 41% males and 59%
females. Within the adult population, the prevalence of
hypertension was about 26% with a growing trend up to
age 69, with men showing a higher age-specific rate of
hypertension than women. As previously reported in
national and international literature, we confirmed a
direct relationship between body mass index and blood
pressure levels in our populations [30,31]. BP was higher
in ex-smokers than in non smokers or current smokers,
respectively; it was lower in people doing sports; it
increased with increasing LDL, fasting glucose, uricaemia
and potassium; and it was lower in women taking oral
contraceptives. Mean SBP for succeeding age decade inter-
vals shows a tendency to rise progressively in both men
and women, but mean values are always lower in women
than in men. After age 60 the rate of increase becomes
higher in women even if men always show higher SBP. For
both men and women average DBP increases from the
second to the fifth decade of age and tends to slightly
decrease afterward. Overall 70% of the hypertensive pop-
ulation was aware of their condition and 65% were on
anti-hypertensive therapy. Only 41% of the studied sub-
jects currently undergoing treatment for hypertension
exhibited blood pressure within normal limits. Hyperten-
sive females are generally more aware, better treated and
better controlled than males. Most patients under treat-
ment take one drug. The most represented pharmaceutical
classes were agents acting on the Renin-Angiotensin Sys-
tem, followed by beta-blockers and by calcium channel
blockers.
Genetic analysis
In order to analyze our samples we started out breaking
up the Talana EH pedigree creating 16 sub-pedigrees that
include 62 affected subjects and 79 normal controls with
an average 52% genotyped subjects in each pedigree. The
phenotype characteristics of the 141 individuals used in
the genetic analysis are summarized in table 1.
Using MERLIN, we performed two genome wide search
(GWS): the first used 902 uniformly spaced microsatel-
lites while the second used about 16,300 SNPs from the
GeneChip® Human Mapping 500 K Array Set, selected on
the basis of spacing (>150 kb) and informativeness (MAF
> 0.02) in the Talana population. The mean information
content (IC) across 22 autosomal chromosomes for the
full SNP set was uniformly higher than that for the micro-
satellites. The mean genome-wide IC, over all chromo-
somes, was 0.65 (Min: 0.60; Max: 0.68; SD: 0.027) for the
microsatellites while for the SNPs was 0.716 (Min: 0.70;
Max: 0.73; SD:0.009).
A total of nine regions showed significant linkage for the
STRs analysis (LOD SCORES>2.42) and eight suggestive
loci (LOD SCORES>1.77) were founded, while in the
SNPs analysis, the standard threshold of significance do
not allow us to identify significant chromosomic regions
(LOD SCORES > 3.3), but only three suggestive loci (LOD
scores> 1.9) (see Table 2 and Figure 3). Results of the
model-free linkage analysis have evidenced three loci in
both STR and SNP scans and linkage results show a
remarkable degree of similarity (Figures 4) on chromo-
somes 2q24, 11q23.1–25 and 13q14.11–21.33. In addi-
tion, we found concordant results on three locations
through both GWS: 2p23–22, 3p24.1–14.3 and
19q13.41–13.42.
Starting from chromosome 2, STR analysis achieved a sig-
nificant maximum LOD score of 2.96 at position 175.8
Mb on 2q24, spanning a region from 155.7 to 180.8 Mb.
The SNP scan confirmed and refined this locus to a 10 Mb
region (157.1–167.6 Mb). SNPs maximum LOD score
was 2.03 at position 163.5 Mb.
Both GWS show a similar result (STR max LOD = 2.96;
SNP max LOD = 2.45) on chromosome 11q23.1–25. Mic-
rosatellite analysis identified a significant locus from
114.7 to 123.1 Mb with a max peak for D11S1998 (117.2
Mb). SNPs analysis detected a region from 112.8 to 126.6
Mb with maximum LOD of 2.45 at 119 Mb. The inspec-
tion of peaks position obtained with the 2 analyses reveals
that they are in a region where microsatellites coverage
and information content is lower than average compared
to the rest of the chromosome. The mean information
Distribution of genome-wide maximum simulated LOD  scores in each of 1,000 replicate using the STRs markers Figure 2
Distribution of genome-wide maximum simulated 
LOD scores in each of 1,000 replicate using the STRs 
markers.BMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
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content for SNPs was 0.70 (range 0.63–0.75) and for mic-
rosatellites was 0.65 (range 0.55–0.68). This led us to con-
sider the SNPs localization as more precise.
Our double analysis identified an extensive region on
chromosome 13q14.11–21.33. SNPs analysis showed a
locus spanning about 30 Mb (44.9–70.4 Mb) with max
LOD score of 2.09 at 56.3 Mb. The region identified with
STRs is smaller (41.5–54 Mb, peak marker D13S1807,
LOD score 1.86) but it is not well defined because there
are no markers covering the region between 60 and 74
Mb.
On chromosome 19q13.41–13.42 STRs and SNPs analy-
ses show a perfect overlap in a region of about 4 Mb in size
(58.4–62.3 Mb) but the results showed only a suggestive
threshold for STRs analysis. This result is strengthened by
informative sets of markers for both analyses: at 60.2 Mb
with STRs analysis (LOD score 1.96) and at 60 Mb with
SNPs analysis (LOD score 1.60).
For chromosome 3p24.1–14.3, the results we obtained
were suggestive for STRs analysis, given the overlap and
pattern similarity but the statistical significance was lower
what obtained for other loci described in this article.
Therefore we considered the microsatellites IC not satis-
factory for the entire region.
Similar results were obtained on chromosome 2 where
linkage was confirmed both with microsatellites and SNPs
with similar patterns but where the peak values were low
(D2S367 = 1.14 and rs2710605 = 1.44).
The microsatellite NPL analysis found several additional
loci with significant LOD SCORE>2.42 not confirmed by
the biallelic variants analysis. The microsatellites analysis
identifies significant results on the following regions:
1p36.32–36.21, 6p24.1–12.3, 10q25–26, 14q11.2,
15q22–24 and 18q21.1 (see table 2) and suggestive
results on 6q15, 8p22–21.3, 12p13.33–13.1, 17q25.1–
25.3 and 19p13.2–13.12. The large part of them were iso-
lated peaks on a single marker surrounded by negative val-
ues except for the 6p24.1–12.3 locus that partially overlap
to SNPs results with very low LOD score values
(rs4715134 = 1.12). There are several possible explana-
tions for these discordant results such as maps coverage
and differences in IC.
Discussion
We performed Genome-wide Search using two different
systems, STRs and SNPs, with the aim of identifying and
confirming susceptibility loci associated to essential
hypertension by comparing the results obtained. We con-
ducted the analyses on samples obtained in an isolated
founder population (the village of Talana) in which
genetic heterogeneity and environmental noise are likely
to be reduced.
We carried out a careful epidemiological investigation of
Talana's population in order to assess the environmental
and clinical features of the selected object of our study.
This section of the study is important because there are
very few epidemiological studies in particular in Sardinia
where we have limited epidemiological data coming pri-
marily from the main hospitals in Cagliari (the main city
Table 2: Summary of results in both genome wide scans using 902 autosomal microsatellites and 16.300 biallelic markers. 
Chromosome Microsatellites SNPs
Peak marker Position (Mb) LOD score Peak marker Position (Mb) LOD score
1p36.32–36.21 D1S468 3.6–9.5 2.75 *
2q24 D2S2981 155.7–180.8 2.96 * rs9287822 157.08–167.62 2.03
3p24.1–14.3 D3S2432 27.9–49.4 1.86 rs10490772 43.07–54.91 1.45
6p24.1–23 D6S1006 12.96–14.06 2.50 *
6p21.1–12.3 D6S1017 41.7–50.7 3.75 * rs4715134 48.77–50.04 1.12
6q15 D6S462 90.98 1.78
8p22–21.3 D8S560 17.9–21.6 2.06
10q25–26 D10S597 111.2–119.1 3.18 *
11q23.1–25 D11S1998 114.7–123.1 2.96 * rs7949154 112.8–126.6 2.45
12p13.33–13.1 D12S374 3.5–13.5 2.30
13q14.11–21.33 D13S1807 41.5–54.0 1.86 rs7333137 44.9–70.4 2.09
14q11.2 D14S742 19.9–21.7 2.51 *
15q22–24 D15S131 64.3–72 3.80*
17q25.1–25.3 D17S2195 70.2–73.4 2.01
18q21.1 D18S970 33.1–51.5 2.62 *
19p13.2–13.12 D19S586 8–12.5 2.05
19q13.41–13.42 D19S418 58.4–62.3 1.96 rs11672983 58.89–61.11 1.6
Significant values are in boldface with asterisk (*), suggestive in boldface.BMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
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Multipoint LOD scores for all autosomal chromosomes Figure 3
Multipoint LOD scores for all autosomal chromosomes. Each panel shows the chromosome number with the length in 
megabases (Mb) in abscissa and the LOD scores in ordinate (microsatellites-dotted line; SNPs-solid line).
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of the island). The first phase of the study had the purpose
of determining the prevalence of common diseases and
quantitative traits presenting familial aggregation. One of
the aims was to verify if the essential hypertension clinical
and epidemiological features found in this peculiar isolate
are comparable with those observed in large out-breeding
populations. Prevalence, determinants, awareness and
treatments of hypertension were comparable and similar
in trend to those reported in large epidemiological sur-
veys. We found that the prevalence of hypertension in the
village was about 26%, pretty close to the 27% prevalence
worldwide. Hypertension prevalence for Talana was lower
than that published by the Italian Istituto Superiore di
Sanità for Sardinia as a whole they report a prevalence of
EH of 29% in females and 33% in males considering as
hypertensive a subject with a SBP/DBP > 160/95 mm Hg
or under pharmacological treatment, while for Italy as a
whole, they report a prevalence of hypertension of 31% in
females and 33% in males. Although we used less restric-
tive criteria we found a lower prevalence of EH in these
isolated villages. This result could be due to the substan-
tially rural nature of these communities, characterized by
a healthier environment, nutrition and life style. Similar
conclusions have been suggested in studies carried out in
several countries, where it has been found that the mean
blood pressures of subjects living in transitional and
urban areas were significantly higher than those of sub-
jects in rural areas [32,33]. Ogliastra estimates are compa-
rable to those described in non Hispanic whites and
Mexican Americans and they are lower than those
described in the other countries.
We performed a non parametric linkage analysis, the most
common approach used when, as in the case of EH, it is
not possible to define a clear transmission pattern within
families. To gain in power in order to detect linkage we
performed two genomewide search, the first using micro-
satellites and the second using SNPs to benefit from a
more dense map and from higher IC [34]. We decide to
use four generation families in reason of the minimal loss
of IC. Sub pedigrees connecting more distantly related
affected individuals tend to include more non-genotyped
ancestors/individuals, which may lead to smaller ICs and
therefore decrease power [35]. We performed additional
analyses using different sets of families, starting from the
same cohort of patients, created by different software
(GREFFA, PedCut) and using different linkage software
(data not shown), and we confirmed the same loci with
the same peak markers of the analysis described in the
results section.
We identified several loci associated to EH. We considered
particularly relevant the loci with significant e/o sugges-
tive LOD scores obtained both with SNPs and STRs scans.
Further support to consideration of positive loci came
from their previous association to hypertension or to car-
diovascular disease phenotypes in the published litera-
ture.
The potential importance of the identified locus on chro-
mosome 2q24 in the control of blood pressure is sup-
ported by previous genome-wide scans and association
studies in other human populations. Specifically, 5
genome-wide linkage screens detected a signal overlap-
ping with our region and we can make a direct compari-
son of the chromosome 2q locus identified in Talana
families with the other studies. Zhu et al, [36] found link-
age to chromosome 2q in Chinese hypertensive sibling
Multipoint LOD scores for each chromosome that showed  the most significant results Figure 4
Multipoint LOD scores for each chromosome that 
showed the most significant results. Each panel shows 
the chromosome number with the length in megabases (Mb) 
in abscissa and the LOD scores in ordinate (microsatellites-
dotted line; SNPs-solid line).
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pairs and found a linkage peak around marker D2S142.
The same marker represent also 1 of 4 loci associated with
hypertension in the BRIGHT study performed in 1599
severely hypertensive British families [37]. Two independ-
ent GWS on Finnish population found suggestive evi-
dence of linkage for hypertension on chromosome 2q: the
first identified a 17-cM region from 169.4 to 186.8 cM
[38] and the second split the region suggesting 2 suscepti-
bility loci with a peak (LOD = 1.8), adjacent to our candi-
date region. Recently, in a Kyrgyz family in which
hypertension appears at an early age and where several
family members have suffered stroke, genome-wide link-
age screen and critical recombination events observed
within this family suggest that an hypertension associated
locus may lie within a single <10-cM area of chromosome
2q24.3 to q31.1 between markers D2S2380 and D2S335
[39] with a LOD score of 2.67 for marker D2S2330. More-
over, in hypertensive rat models a blood-pressure quanti-
tative trait locus located on rat chromosome 9q22-q34
exhibits high homology with our region of interest on 2q.
Furthermore, we have recently published a linkage study,
that identified a locus for total serum cholesterol and LDL
cholesterol on chromosome 2q21.2-q24.1 [40]. In light of
the high BMI values in our population, we can suppose
the presence of a common variant underlying HTN and
cholesterol confirming a possible direct relationship
between BMI, lipid profiles and blood pressure levels in
our populations.
Our SNPs analysis restricted the candidate region to the
first part of the identified region. The current release of the
human genome assembly, indicates that the 2q24.3 to
q31.1 region between markers rs526540 and rs3914147
(157.081 to 167.624 Mb) encompasses 70 genes of
known or predicted function. None of the genes responsi-
ble for the monogenic forms of hypertension are found
within this region. However, we have identified 5 well-
characterized sodium channels, voltage-gated alpha subu-
nit genes (SCN1A, SCN2A, SCN3A, SCN7A and SCN9A)
that could be considered biologically plausible candi-
dates. Particularly, SCN7A codes for the a-subunit of a car-
diac and skeletal muscle sodium channel protein. A
polymorphism in exon 18 of this gene was associated with
essential hypertension among the Chinese Han popula-
tion of Shanghai, China [41]. Recently the major allele T
of the cv356952 biallelic marker was significantly associ-
ated with higher left ventricular mass index in a cohort of
hypertensive black siblings [42].
Furthermore, 4 biallelic markers with the highest LOD
score were placed on the potassium voltage-gated chan-
nel, subfamily H (eag-related), member 7 gene (KCNH7).
Two markers are located on the gene (rs9287822,
rs4667468) and the others lie in the strong linkage dise-
quilibrium section of the 3' region of the gene
(rs11900934, rs16848123). The voltage-gated potassium
channels represent the most complex class of voltage-
gated ion channels from both functional and structural
standpoints. Their diverse functions include regulating
neurotransmitter release, heart rate, insulin secretion,
neuronal excitability, epithelial electrolyte transport,
smooth muscle contraction, and cell volume. Murine
models proved that ion channels encoded by ether-à-go-
go-related genes (eag) have been implicated in re-polari-
zation of the cardiac action potential and also as compo-
nents of the resting membrane conductance in various
cells [43].
We also confirmed the association of hypertension related
phenotypes to the 11q region detected by 2-stage genome
screen on Caucasian in United Kingdom [44]. Sib-pair
linkage analysis identified a single locus on chromosome
11q on the same marker we identified with our GWS assay
(D11S925). In addition, the same locus was replicated in
the HERITAGE Family Study on black individuals [45]. In
this genomic region, close to the highest peak we identi-
fied two genes encoding for sodium channels (SCN4B
and SCN2B). Four different β-subunits have been
described and all are detectable in cardiac tissue. Recently,
a missense mutation (L179F) of the SCN4B gene was
associated to heritable arrhythmia syndrome throughout
a 3-generation pedigree and it is surmised that it may con-
tribute to the alteration of the cardiac sodium channel
current [46].
Regarding the 13q14.11–21.33 locus, the genomic region
identified in our study is not well enough defined to jus-
tify a gene search since both STRs markers and SNPs anal-
yses do not consent to focus on a restricted area. But also
in this case, we find the same location associated to hyper-
tension in meta-analysis and other genome scans reported
in literature [47,48].
On chromosome 19 we found a STRs suggestive region
with a precise overlap between SNPs and STRs analysis in
a region of only 4 Mb in size. As previously, we replicated
a suggestive result obtained on a cohort of 1174 individu-
als (562 males and 612 females) that were classified as
having hypertension from the Framingham Heart Study.
This genomic interval includes several potential candidate
genes and in particular a cluster of three gamma subunit
genes: CACNG6, CACNG7 and CACNG8.
Finally, particular attention was focused on the first part
of chromosome 2 where, in a previous study, we identi-
fied an hypertension associated locus carrying out GWS
on a single Talana family [49]. In that study, we utilized a
less dense map of markers, about 400 microsatellites, and
we selected only the most severely hypertensive subjects
(diastolic blood pressure (DBP) >100 mm Hg) belonging
to a single deep-rooted pedigree (12 generations). TheBMC Medical Genetics 2009, 10:81 http://www.biomedcentral.com/1471-2350/10/81
Page 12 of 13
(page number not for citation purposes)
present analysis confirmed the signal both with microsat-
ellites and SNPs, the 2 different GWS presenting similar
patterns, on the 2p22–23 region shifting the previous sig-
nal of about 8 Mb but the peak values were low (D2S367
= 1.14 and rs2710605 = 1.44). The pattern of our results
using STRs and SNPs have a high similarity with the sig-
nals detected by Caulfield et al., [31] for the entire chro-
mosome 2 and validate the association of this locus to
hypertension. In recent times, a number of studies
focused on hypertension and on QTLs influencing blood
pressure confirmed this candidate locus in a region that
reach over 2p24–25 to 2p22–23 in Chinese, Mexican
American, African and African American, Caucasian and
British people [50-56].
Conclusion
The genome-wide screens published to date for hyperten-
sion genes are diverse in phenotype, ethnic origin, selec-
tion criteria, numbers and structures of families and range
from analysis of single large pedigrees to various hun-
dreds of sib-pairs or families. Our genome-wide scan dif-
fers from many others because to gain in power in order
to detect linkage we performed two genomewide search,
the first using microsatellites and the second using SNPs
to benefit from a more dense map and from higher IC in
the same group of families from a little village. The loci we
identified in this study are clearly unlikely to reflect all the
potential genetic effects on EH. However, our results
prove that our population possesses genetic characteristics
comparable to outbreeding population since the four loci
identified in this study confirm previously identified
genomic regions in association with blood pressure dis-
ease phenotypes. We are going to replicate our positive
results in a large scale cohort of subjects from other vil-
lages in the same area in order to study a population with
a highly homogenous genetic background as is the people
from Ogliastra and it is useful to conduct further analysis
to restrict the regions of interest and identify the genes
involved in the etiology of EH.
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